Siolta Therapeutics to Present Phase 2 ADORED Trial Results at AAAAI 2026 Siolta Therapeutics will present its findings from the Phase 2 ADORED trial during AAAAI 2026, showcasing promising results in at-risk infants.

Siolta Therapeutics to Present Phase 2 ADORED Trial Results at AAAAI 2026 #USA #Philadelphia #Siolta_Therapeutics #STMC-103H #ADORED_trial

Siolta Therapeutics Achieves Promising Phase 2 Results for STMC-103H in Preventing Allergic Diseases Siolta Therapeutics has announced encouraging Phase 2 results for STMC-103H, showing significant potential in preventing allergic diseases in at-risk infants.

Siolta Therapeutics Achieves Promising Phase 2 Results for STMC-103H in Preventing Allergic Diseases #USA #San_Carlos #Siolta_Therapeutics #STMC-103H #ADORED_Study